Article

HLA Genotype is Associated With Clinical Outcomes to anti-PD1 Therapy in Advanced Melanoma

2022-02-28

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold>Predictive biomarkers of response to immune checkpoint inhibitors (ICI) are currently being evaluated in many studies. We evaluated whether germline Human Leukocyte Antigen (HLA) status can influence the response to immunotherapy.<bold>Materials and Methods:</bold>Advanced melanoma patients undergoing treatment with pembrolizumab were recruited between August 201...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b55033c4-209d-572c-aee4-4e0600490dec
DOI: 10.21203/rs.3.rs-1360151/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

HLA Genotype is Associated With Clinical Outcomes to anti-PD1 Therapy in Advanced MelanomaDOI 10.21203/rs.3.rs-1360151/v1Read

MHC class I and class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanomaSemantic proximity Read

HLA genotyping meets response to immune checkpoint inhibitors prediction: A story just started.Semantic proximity Read

Computing Skin Cutaneous Melanoma Outcome From the HLA-Alleles and Clinical CharacteristicsSemantic proximity Read

Retrospective analysis of cutaneous immune-related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA-B*51:01 allele.Semantic proximity Read

Computing Skin Cutaneous Melanoma Outcome from the HLA-alleles and Clinical CharacteristicsSemantic proximity Read

Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 AnalysisSemantic proximity Read

Association between cancer risk and HLA genotype can be explained by anti-tumor immunitySemantic proximity Read

Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma.Semantic proximity Read

Enhanced expression of HLA-DR and CD69 on peripheral CD4 <sup>+</sup> T cells predicts better clinical outcomes in cutaneous melanomaSemantic proximity Read

Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitor as first-line therapySemantic proximity Read

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapySemantic proximity Read

Germline variants in exonic regions have limited impact on immune checkpoint blockade clinical outcomes in advanced melanoma.Semantic proximity Read